Algae-based compound for gut inflammation and pain relief
Part of Digestive system, Pain clinical trials.
This study tests if a natural algae-based compound can help prevent or treat inflammation and pain in people with Crohn's disease or ulcerative colitis. You may be asked to join if you are already scheduled for a routine endoscopy and biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ulcerative colitis or Crohn's disease, or you are having an endoscopy for another reason (like cancer screening or irritable bowel syndrome).
- You are between 2 and 60 years old.
- You are already scheduled for an endoscopy and biopsy as part of your normal care.
- For ulcerative colitis: your Mayo score is 2 or higher (doctors will check this).
- For Crohn's disease: your Harvey-Bradshaw score is 5 or higher and your endoscopy score is above 2.
- If you do not have IBD, you cannot be on anti-inflammatory or immune-suppressing medications for other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study looks at bacteria in your gut that may produce chemicals linked to ongoing pain in Crohn's disease or ulcerative colitis, even when the disease itself is not very active. Researchers want to understand why some people still have moderate to severe abdominal pain even after their inflammation has calmed down.
This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.
This trial tests a new drug that blocks a protein called TREM-1, which may help reduce inflammation in the gut. It uses tissue samples from people with active ulcerative colitis or Crohn's disease to see if the drug is effective.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
Hear when a new IBD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.